Company: PMVC
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001213900-25-107610
Chunk: 253

Company: PMV Consumer Acquisition Corp.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 4
Chunk 253
---
 manner that you do not support, including amendments to our certificate of incorporation.

Further,
holders of our Founder Shares will be entitled to ten (10) votes for each Founder Share held at any annual or special meeting of stockholders
or in the case of any written consent of stockholders in lieu of a meeting and for all purposes. Holders of our public shares will be
entitled to one vote for each such share. Additionally, only holders of our Founder Shares will have the right to vote on the election
of directors. Holders of our public shares will not be entitled to vote on the election of directors.

We
may amend the terms of the warrants in a manner that may be adverse to holders of public warrants with the approval by the holders of
at least 50% of the then outstanding public warrants. As a result, the exercise price of your warrants could be increased, the exercise
period could be shortened and the number of shares of our Class A common stock purchasable upon exercise of a warrant could be decreased,
all without your approval.

Our
warrants were issued in registered form under a warrant agreement between Continental Stock Transfer & Trust Company, as warrant
agent, and us. The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder to cure
any ambiguity or correct any defective provision, but requires the approval by the holders of at least 50% of the then outstanding public
warrants to make any change that adversely affects the interests of the registered holders of public warrants. Accordingly, we may amend
the terms of the public warrants in a manner adverse to a holder if holders of at least 50% of the then outstanding public warrants approve
of such amendment (which would include any public warrants purchased by our Sponsor or any of our officers or directors).

Although
our ability to amend the terms of the public warrants with the consent of at least 50% of the then outstanding public warrants is unlimited,
examples of such amendments could be amendments to, among other things, increase the exercise price of the warrants, convert the warrants
into cash, shorten the exercise period or decrease the number of shares of Class A common stock purchasable upon exercise of a warrant.

28

We
are an emerging growth company within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure
requirements available to emerging growth companies, this could make our securities less attractive to investors and may make it more
difficult to compare our performance with other public companies.